Back to search
A phase II trial of amrubicin (AMR) for recurrent or refractory small cell lung cancer (SCLC)
Data up to Jan 2025
Published2006
Citations4
References0
Total Citations Per Year
Abstract
References (0)
No references found
Cited By (0)
No citing papers found in database